Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 752-760

  Denimal, Damien ^a,b   Pais de Barros, Jean Paul ^a   Petit, Jean Michel ^a,c   Bouillet, Benjamin ^a,c   Vergès, Bruno ^a,c   Duvillard, Laurence ^a,b  

^a UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c HÔPITAL DU BOCAGE   (France)

Author keywords

HDL; Lipidomics; Plasmalogens; Sphingosine 1 phosphate; Tandem mass spectrometry; Type 1 diabetes

Indexed keywords

APOLIPOPROTEIN M; CERAMIDE; CHOLINE; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PLASMALOGEN; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; HIGH DENSITY LIPOPROTEIN; LIPID; LYSOPHOSPHOLIPID; PHOSPHOLIPID; SPHINGOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INVESTIGATIVE PROCEDURES; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; METABOLISM; MIDDLE AGED;

ADULT; CERAMIDES; CHOLESTEROL, HDL; CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; PLASMALOGENS; SPHINGOLIPIDS; SPHINGOSINE; TANDEM MASS SPECTROMETRY;

EID: 84934344254     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.040     Document Type: Article

References (44)

1. Laing S.P., Swerdlow A.J., Slater S.D., Burden A.C., Morris A., Waugh N.R., et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003, 46:760-765.
2. Jørgensen M.E., Almdal T.P., Carstensen B. Time trends in mortality rates in type 1 diabetes from 2002 to 2011. Diabetologia 2013, 56:2401-2404.
3. Brock J.W., Jenkins A.J., Lyons T.J., Klein R.L., Yim E., Lopes-Virella M., et al. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J. Lipid Res. 2008, 49:847-855.
4. Marcovecchio M.L., Dalton R.N., Prevost A.T., Acerini C.L., Barrett T.G., Cooper J.D., et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care 2009, 32:658-663.
5. Colhoun H.M., Taskinen M.R., Otvos J.D., Van Den Berg P., O'Connor J., Van Tol A. Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 2002, 51:3300-3305.
6. Guy J., Ogden L., Wadwa R.P., Hamma R.F., Mayer-Davis E.J., Liese A.D., et al. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for diabetes in youth case-control study. Diabetes Care 2009, 32:416-420.
7. Ferretti G., Bacchetti T., Busni D., Rabini R.A., Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J. Clin. Endocrinol. Metab. 2004, 89:2957-2962.
8. Perségol L., Foissac M., Lagrost L., Athias A., Gambert P., Vergès B., et al. HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia 2007, 50:2384-2387.
9. Brindisi M.C., Duvillard L., Monier S., Vergès B., Perségol L. Deleterious effect of glycation on the ability of HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation. Diabetes Metab. Res. Rev. 2013, 29:618-623.
10. Hoang A., Murphy A.J., Coughlan M.T., Thomas M.C., Forbes J.M., O'Brien R., et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 2007, 50:1770-1779.
11. Meikle P.J., Wong G., Tsorotes D., Barlow C.K., Weir J.M., Christopher M.J., et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2723-2732.
12. Kontush A., Therond P., Zerrad A., Couturier M., Négre-Salvayre A., de Souza J.A., et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1843-1849.
13. Kontush A., Lhomme M., Chapman M.J. Unraveling the complexities of the HDL lipidome. J. Lipid. Res. 2013, 54:2950-2963.
14. Camont L., Lhomme M., Rached F., Le Goff W., Nègre-Salvayre A., Salvayre R., et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2715-2723.
15. Argraves K.M., Sethi A.A., Gazzolo P.J., Wilkerson B.A., Remaley A.T., Tybjaerg-Hansen A., et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011, 10:70.
16. Sattler K., Lehmann I., Gräler M., Bröcker-Preuss M., Erbel R., Heusch G., et al. HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis. Cell. Physiol. Biochem. 2014, 34:172-184.
17. Selam J.L., Kashyap M.L., Gupta A.K., Turner D., Wong N.D., Lozano J.L., et al. Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery. Metabolism 1994, 43:665-669.
18. Bagdade J.D., Dunn F.L., Eckel R.H., Ritter M.C. Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin-dependent diabetes mellitus. Arterioscler. Thromb. 1994, 14:1933-1939.
19. de Vries R., Kerstens M.N., Sluiter W.J., Groen A.K., van Tol A., Dullaart R.P. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005, 48:1105-1113.
20. Executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001, 285:2486-2497.
21. Duvillard L., Caslake M.J., Petit J.M., Vergès B., Gambert P., Packard C.J. Distinct patterns of heparin affinity chromatography VLDL1 and VLDL2 subfractions in the different dyslipidaemias. Atherosclerosis 2008, 199:27-33.
22. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957, 22:497-509.
23. Bielawski J., Pierce J.S., Snider J., Rembiesa B., Szulc Z.M., Bielawska A. Comprehensive quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods Mol. Biol. 2009, 579:443-467.
24. Hammad S.M., Pierce J.S., Soodavar F., et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J. Lipid Res. 2010, 51:3074-3087.
25. Wiesner P., Leidl K., Boettcher A., Schmitz G., Liebisch G. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J. Lipid Res. 2009, 50:574-585.
26. Myher J.J., Kuksis A., Shepherd J., Packard C.J., Morrisett J.D., Taunton O.D., et al. Effect of saturated and unsaturated fat diets on molecular species of phosphatidylcholine and sphingomyelin of human plasma lipoprotein. Biochim. Biophys. Acta 1981, 666:110-119.
27. Scherer M., Böttcher A., Schmitz G., Liebisch G. Sphingolipid profiling of human plasma and FPLC-separated lipoprotein fractions by hydrophilic interaction chromatography tandem mass spectrometry. Biochim. Biophys. Acta 2011, 1811:68-75.
28. Yetukuri L., Huopaniemi I., Koivuniemi A., Maranghi M., Hiukka A., Nygren H., et al. High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. PLoS One 2011, 6:e23589.
29. Bagdade J.D., Helve E., Taskinen M.R. Effects of continuous insulin infusion therapy on lipoprotein surface and core lipid composition in insulin-dependent diabetes mellitus. Metabolism 1991, 40:445-449.
30. Bagdade J.D., Ritter M.C., Subbaiah P.V. Accelerated cholesteryl ester transfer in patients with insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 1991, 21:161-167.
31. Bagdade J.D., Knight-Gibson C., Simpson N., Gerkin R., Alaupovic P., Reardon C. CETP-mediated cholesteryl ester enrichment of apoB subclasses in type 1 diabetes. Eur. J. Clin. Invest. 2012, 42:709-716.
32. Potì F., Simoni M., Nofer J.R. Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P). Cardiovasc. Res. 2014, 103:395-404.
33. Nofer J.R., van der Giet M., Tölle M., Wolinska I., von Wnuck Lipinski K., Baba H.A., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J. Clin. Invest. 2004, 113:569-581.
34. Kimura T., Tomura H., Sato K., Ito M., Matsuoka I., Im D.S., et al. Mechanism and role of high density lipoprotein-induced activation of AMP-activated protein kinase in endothelial cells. J. Biol. Chem. 2010, 285:4387-4397.
35. Kimura T., Tomura H., Mogi C., Kuwabara A., Damirin A., Ishizuka T., et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J. Biol. Chem. 2006, 281:37457-37467.
36. Argraves K.M., Gazzolo P.J., Groh E.M., Wilkerson B.A., Matsuura B.S., Twal W.O., et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J. Biol. Chem. 2008, 283:25074-25081.
37. Theilmeier G., Schmidt C., Herrmann J., Keul P., Schäfers M., Herrgott I., et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006, 114:1403-1409.
38. Sugiura T., Dohi Y., Yamashita S., Ohte N., Ito S., Iwaki S., et al. Analytical evaluation of plasma serotonin and sphingosine 1-phosphate and their clinical assessment in early atherosclerosis. Coron. Artery Dis. 2012, 23:234-238.
39. Christoffersen C., Obinata H., Kumaraswam S.B., Galvani S., Ahnström J., Sevvana M., et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9613-9618.
40. Karuna R., Park R., Othman A., Holleboom A.G., Motazacker M.M., Sutter I., et al. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 2011, 219:855-863.
41. Broniec A., Klosinski R., Pawlak A., Wrona-Krol M., Thompson D., Sarna T. Interactions of plasmalogens and their diacyl analogs with singlet oxygen in selected model systems. Free Radic. Biol. Med. 2011, 50:892-898.
42. Levy M., Futerman A.H. Mammalian ceramide synthases, IUBMB. Life 2010, 62:347-356.
43. Guha M., Gantz D.L., Gursky O. Effects of acyl chain length, unsaturation, and pH on thermal stability of model discoidal HDLs. J. Lipid Res. 2008, 49:1752-1761.
44. Bagdade J.D., Subbaiah P.V. Whole-plasma and high-density lipoprotein subfraction surface lipid composition in IDDM men. Diabetes 1989, 38:1226-1230.